Thus, effect of SGLT2 inhibitors on LV function is multifactorial [34–36], so that GLS-guided management using dapagliflozin for T2DM with stable HF may therefore potentially be able to prevent progression to later HF and may offer new insights into the management of T2DM with HF. Here, SLC5A2 is linked to type 2 diabetes mellitus.